Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07464587 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease

StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoint added 2 → 3 primary endpoints
See other at-risk trials from Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Record History

  1. Primary endpoint(s) modified Recruitment opened · Trial sites reduced: 79 → 54 locations · Completion pushed from Apr 2027 to Nov 2027 · 2 more Show 5 more changesShow less
    • Recruitment opened
    • Trial sites reduced: 79 → 54 locations
    • Completion pushed from Apr 2027 to Nov 2027
    • Start date changed from estimate of Mar 2026 to Apr 14, 2026
    • Eligibility criteria shortened, about 14 words
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To evaluate the safety of inhaled TQC3721 Suspension in patients with moderate to severe Chronic Obstructive Pulmonary Disease
Trial Details
NCT Number NCT07464587
Lead Sponsor Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions Chronic Obstructive Pulmonary Disease
Enrollment 800 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov